Entering text into the input field will update the search result below

Verve announces dosing initiation in Phase 1 trial for base editing candidate

Jul. 12, 2022 7:10 AM ETVerve Therapeutics, Inc. (VERV)BLUE, BEAMBy: Dulan Lokuwithana, SA News Editor

Genetic engineering

Andy/iStock via Getty Images

Development-stage biotech Verve Therapeutics (NASDAQ:VERV) announced on Tuesday that the company dosed the first patient in an early-stage trial for its lead asset and the in vivo base editing candidate VERVE-101.

The heart-1 clinical trial

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.